12.22.2021
Pharmaceutical Daily: “Akston Biosciences Announces Positive Top-Line Data From Phase II Study of COVID-19 Vaccine in the Netherlands”
Pharmaceutical Daily (Twitter): “Akston Biosciences Announces Positive Top-Line Data From Phase II Study of COVID-19 Vaccine in the Netherlands”
BioSpace: “Akston Biosciences Announces Positive Top-Line Data From Phase II Study of COVID-19 Vaccine in the Netherlands”
Boston Cambridge BioTech Netwrks: “BCBN Feed: Akston Biosciences Announces Positive Top-Line Data From Phase II Study of COVID-19 Vaccine in the Netherlands”
12.21.2021
Medical Dialogues: “Consumption of Pro-Inflammatory Diet Increases Likelihood of Frialty Onset in Older Adults”
12.20.2021
C&EN: “European drug service firms are changing hands: Private investors are behind deals for Seqens, Novasep, and Johnson Matthey’s business”
12.17.2021
PE Hub: “SK Capital buys SEQENS: SK Capital acquires SEQENS, a provider of pharmaceutical services and specialty ingredients”
Private Equity Wire: “SK Capital Partners acquires SEQENS”
AcroFan: “Change in SEQENS’ Shareholding Structure – SEQENS Is Now Stronger, More Focused and Positioned as One of the World’s Leading Players in Pharma”
Yahoo!: “Change in SEQENS’ Shareholding Structure – SEQENS Is Now Stronger, More Focused and Positioned as One of the World’s Leading Players in Pharmaceutical Solutions and Specialty Ingredients”
BizDallies: “SK Capital has acquired SEQENS, a provider of pharmaceutical solutions and specialty ingredients”
NewsCenter (Greece): “Second generation vaccines are coming, only for the rich”